Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. - Wikidata - awgldk - TriplyDB

Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

http://www.wikidata.org/entity/Q35112676

about

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review Tropical and travel-associated norovirus: current concepts Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine Norovirus Narita 104 virus-like particles expressed in Nicotiana benthamiana induce serum and mucosal immune responses Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function.Infection control for norovirus.Burden of norovirus in healthcare facilities and strategies for outbreak control.The potential economic value of a human norovirus vaccine for the United States.Strategies for intranasal delivery of vaccines Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age.Comparative evaluation of recombinant protein production in different biofactories: the green perspective.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Optimizing efficacy of mucosal vaccines.Adjuvanted influenza vaccines.Bioengineering virus-like particles as vaccines.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Prospects and Challenges in the Development of a Norovirus Vaccine.Plant-made pharmaceuticals: from 'Edible Vaccines' to Ebola therapeutics.Assessment of Functional Norovirus Antibody Responses by Blocking Assay in Mice.Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography.Overcoming barriers in the mucosal delivery of virus-like particle-based vaccines.Intranasal immunization with dry powder vaccines.Development of a synthetic Vi polysaccharide vaccine for typhoid fever.

P2860

Q26775082-79735F72-3474-4FAE-AF0A-BBDC59B063BC Q26783083-6B301440-1289-4AC1-9A39-7BFA5A2D534F Q26799737-F4111467-1C71-467F-8BB8-43E609B10358 Q28728786-085B6AE7-1681-4EEF-94F6-1B597A6BD1FA Q33681834-6B90310B-3483-4A2C-834B-5FCDE51984D8 Q33703664-03EDE079-D2C5-4F01-A99A-5BA568179A1C Q34290717-B20C063F-C64B-4380-9805-FBDFBEB168E6 Q34907018-21DA3EA5-48A4-4CFF-96B5-3A1D9CEA5D58 Q35824686-9D6C93E4-A14B-4DF5-BE16-2A56C2CF72F1 Q36017750-FCE3E5B2-AE62-4780-ABC9-D8B44026FBF8 Q36071784-11C88297-4C78-4147-8A5D-1D2EA6A26692 Q36219295-10E342E8-2B3D-41C4-A060-648BFFDE156D Q36344240-9BB7AF02-B9AE-41D5-BAF0-904DE4CABEE1 Q36455283-00021D93-C403-4A4F-A83A-3BD321D59FAA Q36514771-66C19C67-9C9B-41E8-A07F-2AA361F2619A Q36642590-6CB69B6B-FF6F-4B2C-9AB5-24451F90BAC9 Q36858686-A95545B4-923E-4F8B-B040-B3B9998BC59A Q37018558-12CA43C1-C756-4760-AAC4-B586EC3D65E4 Q37109677-1CD306CE-67D3-45ED-850E-C5D3678BA434 Q37679720-E17A63EB-9795-4789-9A4D-1EE01138D248 Q37951525-63668BBD-0D18-4AE4-9953-5C545E75A971 Q38059754-871D8CE6-8F9E-48E4-A7BF-6632FD32DCD4 Q38140045-2C29F86E-BB88-4A10-AEFF-8DB0DCC9FC3C Q38172045-94355AE8-B89E-4B29-87D8-743D24929ED5 Q38461061-AD17515C-164C-43B7-A338-8FE2C202683C Q40044140-74FF5E4F-064A-47CE-8D39-21D80D06F7EC Q40102851-61BBD0AB-F372-413F-8F99-29A4F5C51ED4 Q40140378-6CB16ED2-4D74-4DC5-AD8C-657B04325CD5 Q40715789-A7E0FEB4-20ED-4451-8E6C-D506738D0A8F Q44197060-8925FE5E-8121-4E09-A60A-F732FE4E7928 Q44939276-33DFA0D5-7F65-46AC-8FB1-25B2A494F6EC Q47584590-1ABBCAF8-BDF8-42F2-9F3B-919C8DE8A77C Q49914721-42C42291-57E5-4A42-8DF6-51A7E9CD3770

P2860

Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

http://www.wikidata.org/entity/Q35112676

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Intranasal delivery of Norwalk ...... u gelling, dry powder vaccine.

@ast

Intranasal delivery of Norwalk ...... u gelling, dry powder vaccine.

@en

type

label

Intranasal delivery of Norwalk ...... u gelling, dry powder vaccine.

@ast

Intranasal delivery of Norwalk ...... u gelling, dry powder vaccine.

@en

prefLabel

Intranasal delivery of Norwalk ...... u gelling, dry powder vaccine.

@ast

Intranasal delivery of Norwalk ...... u gelling, dry powder vaccine.

@en

P1433

Q35112676-4C59B172-B714-4C8C-A1D8-336931B4D681

P1476

Q35112676-B8A10C20-C107-4C3F-A417-11B7A5FEDB43

P2093

Q35112676-0D21D1FD-021B-469B-A38E-F6671AB30A6D

Q35112676-234E5A34-76D9-4EBD-8529-55DD11A5564F

Q35112676-46AEA623-9B4D-49DD-B65E-C8E30C783A24

Q35112676-95A8F728-4075-473A-9EF1-68E5637EE762

Q35112676-9B63B63E-2E29-431C-8F8D-F6CC1F703DD5

Q35112676-AE686143-CA4B-4477-8128-F687AC726F31

Q35112676-BA702545-CBDA-4AFD-8D11-E3FE1691EE4E

Q35112676-C1D3A748-140C-4AA7-968D-CD8C5E6D8F94

Q35112676-EB2A81D8-5B1A-414D-B32B-CA596866EBB7

P2860

Q35112676-05CAD559-5B0B-43E5-91BB-969344FD7188

Q35112676-07B68392-0DA2-4EAE-853A-3A1B57321F7F

Q35112676-1CB1BBE9-7FF0-4295-A944-F7CC9ED31A66

Q35112676-22501342-9382-4079-AFD4-65621261E6BC

Q35112676-2750EFEA-03DE-4DB2-8DBE-B812207D07DE

Q35112676-2B31C0E8-42FD-4ECD-A47E-783E131D1C39

Q35112676-355FA28F-C4D1-4D2C-A68E-C5CD1317373B

Q35112676-35CF9B23-8287-41B3-AC2F-978D9FBFFE1B

Q35112676-42CE12E4-D6CF-47DE-B97D-D8D9A371B54D

Q35112676-4E868CA6-E1F0-42E6-A305-2D35916A5DF1

P304

Q35112676-8AA7B335-B055-44E0-9CCB-1DD69727D909

P31

Q35112676-D229DC93-C662-4DCE-984B-A5527F10412B

P356

Q35112676-53CDA601-0049-443D-AE5D-1F98DAA61D3B

P407

Q35112676-15A3FA99-98E0-417F-9F8D-9504F185F534

P433

Q35112676-B2018131-57FD-4FE3-9BA9-5772B7527887

P478

Q35112676-8795E600-3F4F-44F8-815A-B38228AB0C7A

P577

Q35112676-EF8F9B4B-1B6D-4758-A233-6F8A2608C344

P5875

Q35112676-789CB264-3FA3-4E35-8304-70D61E7D943A

P698

Q35112676-10476993-941D-4E5A-A649-CFC2A162D95D

P921

Q35112676-9E90043F-68BE-46D3-87C3-BF95E352BA2D

P932

Q35112676-1D56E885-AD8F-425E-90AB-A6D989E2F056

P356

J.VACCINE.2011.05.027

P1433

P1476

Intranasal delivery of Norwalk ...... u gelling, dry powder vaccine.

@en

P2093

Alice N Berta

http://www.w3.org/2001/XMLSchema#string

Babu M Medi

http://www.w3.org/2001/XMLSchema#string

Charles J Arntzen

http://www.w3.org/2001/XMLSchema#string

Ian Tizard

http://www.w3.org/2001/XMLSchema#string

Jacquelyn Kilbourne

http://www.w3.org/2001/XMLSchema#string

Lissette S Velasquez

http://www.w3.org/2001/XMLSchema#string

Melissa M Herbst-Kralovetz

http://www.w3.org/2001/XMLSchema#string

Samantha Shira

http://www.w3.org/2001/XMLSchema#string

Yawei Ni

http://www.w3.org/2001/XMLSchema#string

P2860

Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.

Evaluation of mucoadhesive PLGA microparticles for nasal immunization.

Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.

Vaccines for mucosal immunity to combat emerging infectious diseases.

Norwalk virus vaccines: challenges and progress.

Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model.

P304

5221-5231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2011.05.027

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51191079

http://www.w3.org/2001/XMLSchema#string

P698

21640778

http://www.w3.org/2001/XMLSchema#string

P921

P932

3138837

http://www.w3.org/2001/XMLSchema#string